BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the target cut. The analyst views Humacyte’s early commercial traction as evidence of the “game-changing nature” of its Acellular Tissue Engineered Vessel.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA: